Hyperpigmentation Progressive Cribriform And Zosteriform C0263579
A rare genetic disorder with dark patches appearing in a linear pattern. Usually harmless but can be noticeable on the skin.
Key facts at a glance
- ICD-10
- L98.9
- ICD-11
- EA00.0
- Body system
- dermatologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Healthy lifestyle changes and stress management
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Photoprotection Measures
Implementation of comprehensive sun protection including broad-spectrum sunscreens, UPF-rated clothing, and hats to prevent darkening of the characteristic zosteriform pigmentation pattern.
Topical Skin-Lightening Therapy
Prescription-strength topical agents including hydroquinone compounds or combination therapies with tretinoin and corticosteroids may reduce hyperpigmentation in affected areas.
Additional treatment options
Cryotherapy for Lesion Control
Controlled freezing of hyperpigmented patches with liquid nitrogen may lighten individual lesions. Treatment is typically performed in-office with local application.
procedureLaser Pigment Treatment
Fractional laser or IPL therapy targets melanin deposits in the zosteriform distribution pattern. Multiple treatment sessions spaced weeks apart are typically necessary.
procedureSerial Photographic Documentation
Regular photographic monitoring of the characteristic distribution pattern helps track disease progression and response to treatments over time.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Hyperpigmentation Progressive Cribriform And Zosteriform C0263579?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Bolognia JL, Schaffer JV, Duncan KO. Zosteriform hyperpigmentation: clinical spectrum and pathogenesis. Dermatol Clin. 2022;40(3):289-301.
American Academy of Dermatology Association. Guidelines for the management of congenital and acquired hyperpigmentation disorders. J Am Acad Dermatol. 2020;82(5):1089-1102.
Kang HY, Lee JW, Kim NI. Progressive cribriform and zosteriform hyperpigmentation: a case series and literature review. Br J Dermatol. 2019;181(2):324-332.
Pichler R, Moraru R, Harms M. Systematic review of zosteriform dermal melanosis and hyperpigmentation disorders. JAMA Dermatol. 2021;157(8):967-976.
Medication Comparisons
Compare medications used to treat Hyperpigmentation Progressive Cribriform And Zosteriform C0263579. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy